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One of the major targets for breast cancer therapy is the epidermal growth factor receptor (EGFR) and related receptors, which
signal via different signal transduction pathways including the mitogen-activated protein kinase (MAPK) pathway. This study
determined whether there is a correlation between EGFR/HER2 status and MAPK (ERK1/2) phosphorylation in breast cancer cells,
and how this affects the response to an inhibitor of the receptors. Expression of EGFR, HER2 and phosphorylated ERK1/2 were
measured by immunoblotting in a panel of breast cancer cell lines. Several lines expressed high levels of pERK1/2, with no obvious
correlation with the level of EGFR/HER2. The EGFR tyrosine kinase inhibitor PKI166 inhibited growth and induced apoptosis in some
cells with high levels of growth factor receptors (MDA-MB-468, SUM149, SKBR3), but was less effective in cells that also had high
basal ERK1/2 activity (MDA-MB-231). The combination of an inhibitor of MAPK signalling (U0126) and PKI166 produced significantly
more inhibition and apoptosis than either agent alone. This suggests that constitutive activation of the MAPK pathway may bypass
inhibition of EGFR/HER2 tyrosine kinases, and lead to insensitivity to agents targeting the receptors. However, inhibiting both EGFR/
HER2 and MAPK signalling can result in significant growth inhibition and apoptosis of EGFR-expressing breast cancer cells.
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The high mortality rate from breast cancer metastasis has led to
the intensive search for molecular alterations contributing to
metastatic progression, with the aim of designing targeted
therapies (Dillon et al, 1998; Hortobagyi, 2000). Many of these
are now in clinical trials (Kerbel, 2000; Mendelsohn and Baselga,
2000; Posey et al, 2001). Epidermal growth factor receptor (EGFR)
(also known as erbB1) and HER2 (or erbB2) are two widely studied
molecules that are prototypic members of the erbB family of
tyrosine kinase receptors (Olayioye et al, 2000). Other family
members are erbB3 and erbB4. Amplification of the EGFR or erbB2
genes, leading to protein overexpression, occurs frequently in
several human cancers. In breast cancer, EGFR or erbB2 are
overexpressed between 20 and 50% of cases, and increased
expression is associated with shortened disease-free and overall
survival, pointing to involvement in growth regulation of the
tumours (Slamon et al, 1987, 1990; Lacroix et al, 1989; Klijn et al,
1992). The EGFR is an Mr 170000 plasma membrane glycoprotein
that dimerises upon binding ligand (e.g. EGF or TGF-a), resulting
in activation of intrinsic tyrosine kinase activity and tyrosine
autophosphorylation. This triggers a cascade of biochemical and
physiological responses that constitute the mitogenic signal
transduction of the cells. Extensive preclinical studies have shown
that these signalling cascades regulate multiple cellular processes
such as proliferation, differentiation, survival and transformation.
Similar details of HER2 function are less well known and no
soluble ligand for this receptor has been identified. However, this
receptor plays a pivotal role in EGF-mediated signalling, as it is the
preferred and most potent heterodimerisation partner for EGFR
(Graus-Porta et al, 1997).
Several kinase cascades have been implicated in signal
transduction through the erbB receptors (Moghal and Sterenberg,
1999). One of these is the RAS-RAF pathway, leading to the
activation of extracellular signal-regulated kinases (ERKs), one of
the mitogen activated protein kinase (MAPK) cascades (Campbell
et al, 1995). This pathway has been the subject of intense interest
because of its role in the regulation of proliferation, differentiation
and cell–matrix interactions. ERK1 and ERK2 are dually
phosphorylated (pERK) on threonine and tyrosine residues by
mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase (MEK). Activated ERK1/2 phosphorylate and
activate a variety of substrates including transcription factors,
protein kinases and phosphotyrosine protein phosphatases,
leading to positive or negative regulation of signalling cascades
(Campbell et al, 1995). The mitogenic effect of EGF on normal and
malignant mammary epithelia is dependent, at least in part, on
ERK activation (Klapper et al, 2000). Furthermore, mammary
tumour epithelium may exhibit an elevation in basal ERK activity
and sustained ERK activation when stimulated by EGF (Xing and
Imagawa, 1998). The sustained ERK activation may reflect a
difference in the regulation of EGFR activity in the tumour cells vs
normal breast epithelium. Elevated ERK1/2 activity has been noted
in a proportion of clinical breast cancers vs benign disease or
cancer-associated normal epithelium (Sivaraman et al, 1997;
Santen et al, 2002), and a relationship between elevated
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sMAPK activity and shorter disease-free survival in primary
breast cancer has been reported (Mueller et al, 2000; Gee et al,
2001; Adeyinka et al, 2002). Thus, hyperactivity of ERK1/2
may play a role in breast cancer progression. It has been suggested
that this increased activity is related to the pathological
hyperexpression of EGFR and/or HER2 (Von Lintig et al, 2000).
If so, the inhibition of the EGFR/HER2 tyrosine kinase activity
should lead to a decrease in the pERK activity (Albanell et al,
2001). However, if the activation of pERK1/2 is independent of
EGFR/HER2 signalling then increased pERK activity can theore-
tically bypass or over-ride, at least partially, the inhibition of these
growth factor receptors.
Several agents that target one or more members of the ErbB
family of tyrosine kinase receptors are currently under-
going preclinical and clinical investigations (Mendelsohn, 2001;
Slichenmyer and Fry, 2001). In the present study we have
used PKI166 {4-(R)-phenethylamino-6-(hydroxy)phenyl-7H-pyr-
rolo[2,3-d]-pyrimidine}, an inhibitor of the pyrrolopyrimidine
class that has been shown to inhibit the intracellular domain of the
EGF-R kinases with an IC50 of 0.7nM, with less activity against
other tyrosine kinases (Traxler et al, 2001). The goals of the
present study were to characterise the pattern of expression of
activated ERK1/2 in established breast cancer cell lines and
determine whether this correlates with EGFR or HER2 status.
Further, to explore whether activation status of ERK1/2 can be
used as a marker of EGFR kinase inhibition and antiproliferative
effects of agents targeting the growth factor receptors. Our results
indicate that high basal activity of ERKs give some breast cancer
cells a mechanism to escape the inhibitory effects of EGFR/HER2
tyrosine kinase inhibition. However, a combination of agents to
inhibit both EGFR/HER2 and pERK signalling resulted in
significant growth inhibition and induction of apoptosis.
MATERIALS AND METHODS
Breast cancer cell lines
A panel of breast cancer cell lines was used in an initial screen of
cells to study further, based on expression of EGFR, HER2 and
ERK activity. The lines were obtained from the American Type
Culture Collection (Rockville, MD, USA) (T47D, SKBR3, Hs578T,
MCF-7, ZR-75, BT-20), or provided by the Goodwin Institute
(Plantation, FL, USA) (GI101A), Dr Stephen Ethier (University of
Michigan) (SUM149), or Dr Relda Cailleau (UT MD Anderson
Cancer Center) (MDA-MB-231, MDA-MB-435, MDA-MB-468,
MDA-MB-361). Cells were maintained in medium (either MEM,
or DMEM-F12) with 5 or 10% foetal bovine serum and L-
glutamine, in a humidified incubator at 371C with 5%-CO2. Cells of
five cell lines (MDA-MB-231, MDA-MB-435, MDA-MB-468,
SUM149 and GI101A) were injected in the mammary fatpads of
nude mice, as described previously (Price, 1996). The resulting
tumours were collected for preparation of tissue lysates. The use of
animals was approved by the Institutional Animal Care and Use
Committee of the University of Texas MD Anderson Cancer
Center.
Antibodies and inhibitors
Anti-total ERK1/2 and phosphorylated-p44/42 MAPK (Thr202/
Tyr204) antibodies, anti-EGFR and pEGFR antibodies, anti-HER2
and pHER2, anti-p27
kip1, and the MEK1/2 inhibitor UO126 were
purchased from Cell Signalling Technology, Inc., Beverly, MA,
USA. A polyclonal antibody to b-actin was purchased from Sigma
Chemical Co., St Louis, MO, USA). Novartis Pharmaceutical
(through Dr IJ Fidler, UT MD Anderson Cancer Center) provided
PKI166, and a working solution of the tyrosine kinase inhibitor
(5mM in DMSO) was prepared immediately before use.
In vitro growth
Breast cancer cells were plated in 96-well culture plates at an initial
density of 2 10
3 cells per well, and allowed to attach for 24h. The
culture medium was changed and the cells were incubated for a
further 72h in the following: medium alone, or with DMSO (0.1%
volvol
 1), or PKI166 (0.5 or 5.0mM), or UO126 (10mM), or a
combination of UO126 and PKI166. Relative cell numbers were
determined using MTT. The conversion of MTT to formazan in
metabolically viable cells was monitored with an MR-5000
microtiter plate reader reading at 570nm (Dynatech, Inc Chantilly,
VA, USA). All assays were performed in triplicate, with a minimum
of three independent experiments.
Measurement of apoptosis
Apoptosis was assessed by measuring DNA fragmentation by
propidium iodide staining and FACS analysis (Nicoletti et al,
1991). Cells were incubated with PKI166 (0.5 or 5.0mM), with
U0126 (10mM), or a combination for 48h. The cells were harvested,
pelleted by centrifugation and resuspended in PBS with 50mgml
 1
propidium iodide, 0.1% Triton X-100 and 0.1% sodium citrate.
Samples were stored overnight at 41C and vortexed before analysis.
Immunoblotting
Expression of EGFR, HER2, pERK1/2, total ERK1/2 and p27
kip1
were detected by immunoblotting. Protein lysates were prepared
from cultures of cells that were at 80% confluency. For detection of
the effect of PKI166 and/or UO126 on phosphorylation of EGFR
and ERK1/2, lysates were prepared from cultures of cells that were
grown in serum-free medium for 24h prior to addition of the
inhibitors. After 1h incubation with the inhibitors, the cells were
stimulated with 50ngml
 1 EGF for 15min, for assays of EGFR
activation. For protein analysis of tumour lysates, fresh tumour
tissue was homogenised in lysis buffer containing 50mM Tris-HCl,
150mM NaCl, 2mM EDTA and freshly added inhibitors (1mM
Na3VO4,1 m M PMSF, 1mgml
 1 pepstatin A, 2mgml
 1 aprotinin
and 0.5mgml
 1 leupeptin). After homogenisation, NP-40 was
added (1% volvol
 1) and the lysate was mixed, cooled on ice for
30min, and centrifuged at 10000g for 10min Aliquots of 20mg
(tumour lysate) or 20mg (cell culture lysate) of protein were
separated on 7.5% SDS–polyacrylamide gels and electrophoreti-
cally transferred onto nitrocellulose membranes. The membranes
were hybridised with a polyclonal antibody to EGFR, HER2,
pERK1/2 or total ERK1/2, then incubated with an HRP-conjugated
anti-rabbit IgG, and antibodies detected with the Amersham ECL
system (Amersham, Arlington Heights, IL, USA), following the
manufacturer’s recommended procedure. Antibodies were re-
moved by incubating filters in stripping buffer (62.5mM Tris-
HCl, pH 6.7, 2% sodium dodecyl sulphate, 100mM b-mercap-
toethanol). The filters were then hybridised with another primary
antibody, or with antibody to actin to demonstrate equal loading
and transfer of proteins. Immunoreactive bands were quantified by
densitometry using ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA).
RESULTS
Differences in activity of ERK1/2 in the breast cancer cell
lines
Immunoblotting revealed differences in basal levels of ERK1/2
phosphorylation in different breast cancer cell lines, while the
expression of ERK1/2 protein, normalised to actin expression, was
relatively consistent (Figure 1A). To test whether the ERK1/2
activity was only a tissue culture phenomenon, selected cell lines
were injected into the mammary fatpads of nude mice, and protein
EGFR and ERK1/2 phosphorylation in breast cancer
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fact that lysates were of a mixture of tumour cells and surrounding
stromal and infiltrating host cells, the immunoblotting of the
tumour-derived proteins showed similar results to those obtained
using lysates of cultured cells. MDA-MB-231 and MDA-MB-435
tumour lysates showed high levels of p-ERK1/2 in comparison to
MDA-MB-468 and GI101A tumours (Figure 1B).
Elevated ERK activity does not necessarily correlate with
the status of EGFR and HER2 in breast cancer cells
Since ERK1/2 can be activated via EGFR and HER2 signalling,
relative expression levels of these growth factor receptors were
measured in the panel of cell lines, to test if there was a correlation
between ERK activation and receptor expression levels. As
expected from the heterogeneity seen in clinical specimens of
breast cancer, there was variability in expression of EGFR, from
high expression in MDA-MB-468 and minimal expression in MDA-
MB-435 cells (Figure 1A). Comparing these results with the level of
pERK1/2 indicated that there was no direct correlation between
levels of these growth factor receptors and basal levels of ERK1/2
phosphorylation. Thus, while the MDA-MB-231 cell line with
highly activated ERK1/2 expressed a relatively high level of EGFR,
other combinations occur. High pERK1/2 levels were detected in
MDA-MB-435 cells, which have very little EGFR, in contrast to the
SUM149 cells with high EGFR expression and low ERK1/2 activity.
Similarly, no correlation was found between the expression of
HER2 receptor and the status of pERK (Figure 1A).
PKI166 inhibition of breast cancer cell proliferation
Six cell lines with different levels of EGFR expression were selected
for treatment with PKI166. Initial studies used a dose range of 0.1–
5.0mM (data not shown), and the results of treating cells with 0.5
and 5.0mM are shown in Table 1. Growth inhibition was
determined from the results of MTT assays, comparing PKI166
treated cells with cells exposed to medium with 0.1% DMSO.
Treatment with 0.5mM PKI166, a concentration less than plasma
and tumour concentrations achieved in preclinical models from
oral administration of the drug, and the higher dose of 5.0mM,
produced different levels of growth inhibition in different cell
lines. As expected, cells expressing low levels of EGFR and HER2,
GI101A, MDA-MB-435 showed least growth inhibition. However,
not all of the high EGFR-expressing lines were sensitive to PKI166.
The lower dose produced 46 and 21% growth inhibition of
SUM149 and MDA-MB-468 cells, respectively, but had little effect
(3.3% inhibition) on the growth of MDA-MB-231 cells. The SKBR3
cells, expressing EGFR and also high levels of HER2, were most
sensitive, showing 55% growth inhibition with 0.5mM and 76%
inhibition with 5.0mM PKI166.
PKI166 inhibits phosphorylation of EGFR and HER2 in
breast cancer cells
To demonstrate inhibition of EGFR and HER2 phosphorylation by
the concentrations of PKI166 used for the growth inhibition assays,
cell lysates were prepared from MDA-MB-231, MDA-MB-468,
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A  Breast cancer cells in vitro
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Figure 1 (A) Expression of EGFR, HER2, pERK1/2 and total ERK1/2 in lysates of breast cancer cell lines, determined by immunoblotting. Filters hybridised
with antibody against pERK1/2 were re-probed with antibody against total ERK1/2. Densitometry of the immunoreactive bands generated the values shown
under the ERK1/2 panel; these represent phosphorylation of ERK1/2 relative to total ERK1/2 and corrected for equal loading relative to actin (actin for the
ERK1/2 hybridisations not shown). The pERK1/2/ERK1/2 values were then normalised to the value for GI101A cells, the line with the lowest value and
assigned the value¼1. The protein samples used for EGFR and HER2 and actin immunoblots were from different preparations, and are representative of the
results from repeated experiments. (B) Immunoblot showing pERK1/2 and total ERK1/2 in lysates prepared from xenografts of human breast cancer cells.
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stimulation with EGF, and phosphorylation of the receptors
assessed. PKI166 inhibited ligand-induced EGFR phosphorylation
in a dose dependent manner in these four cell lines, and also
phosphorylation of HER2 in SKBR3 cells, in the absence or
presence of 50ngml
 1 EGF (Figure 2) (data for other cell lines not
shown).
Constitutive ERK1/2 phosphorylation as a potential escape
mechanism from inhibition by PKI166
Inhibition of growth by PKI166 was most effective in cells with
high levels of EGFR and nonactivated ERK1/2 (SUM149, MDA-
MB-468) when compared with cells with high EGFR and high basal
level of phosphorylated ERK1/2 (MDA-MB-231). To test whether
the basal ERK1/2 activity was providing an escape mechanism
from inhibition by PKI166, cells were treated with a combination
of PKI166 and UO126, an inhibitor of MEK (Table 1). GI101A cells,
with low EGFR and nonactivated ERK1/2, showed modest growth
inhibition when treated with an individual inhibitor and no
significant difference with the combination of the two. MDA-MB-
435 cells were significantly inhibited by U0126 alone, and the
addition of PKI166 made no difference. The combination of agents
significantly increased the antiproliferative action of PKI166 at the
0.5 and 5.0mM doses in cells expressing higher levels of EGFR or
HER2 (SUM149, MDA-MB-468, SKBR3), including MDA-MB-231
cells. Treating the MDA-MB-231 cells with U0126 alone produced
8.5% inhibition, which was not significantly different from control
values. The addition of U0126 to 0.5 or 5.0mM PKI166 significantly
increased the growth inhibition produced by the receptor tyrosine
kinase inhibitor alone (Table 1).
Apoptosis induced by PKI166 and U0126 was assessed by
measuring DNA fragmentation by propidium iodide staining and
FACS analysis, and determining the proportions of hypodiploid
cells. This showed that PKI166 alone or in combination with U0126
induced apoptosis in the EGFR or HER2 expressing cell lines
MDA-MB-231, MDA-MB-468, SKBR3 and SUM149 cells (Figure 3),
although the proportions of hypodiploid cells varied between the
different lines. Similar to the MTT results in Table 1, SKBR3 and
SUM 149 cells were most sensitive to treatment with the inhibitors,
while the proportions of hypodiploid MDA-MB-231 cells were
lower. Treatment with U0126 alone significantly increased the
numbers of MDA-MB-231 in the G1 phase of the cell cycle (89–
93% compared with 70–72% of control or PKI 166 treated cells,
Po0.001). The proportion of SUM149 cells in G1 was significantly
increased by treatment with either inhibitor alone and the
combination, while apoptosis was significantly increased in cells
exposed to PKI166, with or without U0126. Induction of the cyclin-
dependent kinase inhibitor p27
KIP1 generally corresponded with
increases in the proportion of cells in G1, as shown for MDA-MB-
231 and SUM149 (Figure 4).
Differential effect of PKI166 on ERK1/2 phosphorylation
To evaluate whether the antiproliferative effects of EGFR inhibition
involve ERK1/2 activation, the status of pERK1/2 was determined
in cells exposed to the same concentrations of PKI166 used for the
growth inhibition assays, in the presence and absence of U0126
(10mM) (Figure 5). U1026 alone inhibited ERK1/2 phosphorylation
in MDA-MB-435 cells, with PKI 166 having no effect, as expected
from minimal expression of EGFR in these cells. PKI166 inhibited
ERK1/2 phosphorylation in SUM149 cells, as did U0126 alone, and
further inhibition by the combination of drugs was barely
discernible. Treatment of MDA-MB-468 with either drug resulted
in similar inhibition of ERK1/2 phosphorylation, with almost
complete elimination of phosphorylated proteins by the combina-
tion. PKI166 alone minimally altered the ERK1/2 status in the
MDA-MB-231 cells, and U0126 produced some inhibition, while
the combination resulted in a substantial reduction, reflecting the
effect on cell proliferation and apoptosis. For SUM149 and MDA-
MB-468 cells the combination of the inhibitors almost completely
eliminated ERK1/2 phosphorylation after 1h incubation, although
growth inhibition over 72h was 54–63% with 0.5mM PKI166 plus
10mM U0126, and 63–81% with 5.0mM PKI166 plus 10mM U0126
(Table 1). Recovery of ERK1/2 phosphorylation in the U0126-
treated cells over the period of the growth inhibition assays was
not investigated, but the data may also suggest that other signal
Table 1 Percent growth inhibition of cells of six breast cancer cell lines by the EGFR tyrosine kinase inhibitor PKI166 and the MEK inhibitor U0126
% Mean growth inhibition (s.d.)
U0 PKI (0.5lM) PKI (0.5lM)+U0 PKI (5.0lM) PKI (5.0lM)+U0
MDA-MB-231 8.5 (1.1) 3.3 (0.5) 26.2 (3.5)
a 33.7 (8.1) 61.5 (8.65)
b
MDA-MB-468 24.3 (2.5) 21.1 (1.2) 54.2 (4.2)
a 48.2 (6.8) 63.6 (4.2)
b
SUM149 20.0 (8.9) 46.7 (13.8) 63.2 (5.2)
a 70.8 (4.2) 80.7 (4.2)
b
SKBR3 17.5 (1.3) 55.0 (15.5) 66.3 (4.6) 76.3 (5.3) 86.7 (6.4)
b
MDA-MB-435 68.4 (8.2) 5.2 (2.1) 67.2 (6.3)
a 32.2 (4.2) 74.0 (7.8)
b
GI101A 12.0 (2.3) 13.7 (1.8) 10.0 (1.2) 18.5 (2.3) 23.5 (2.6)
Growth inhibition of cells cultured in the presence of PKI166 (0.5 or 5.0mM) or U0126 (10mM), or the combination for 72h, calculated from MTT assays, and expressed as a
percent growth inhibition compared with cells grown in the presence of DMSO (0.1%) as control. Values shown are mean values from triplicate wells, and are representative of
repeated experiments.
aInhibition by PKI (0.5mM) vs inhibition by PKI (0.5mM)+U0 (Po0.05).
bInhibition by PKI (5.0mM) vs inhibition by PKI (5.0mM)+U0 (Po0.05), analysed using
Student’s t-tests.
EGF –
– – 0.5 0.5 5.0 5.0
+– + – +
PKI (M)
pHER2
HER2
pEGFR
EGFR
Figure 2 PKI166 inhibits phosphorylation of HER2 and EGFR in SKBR3
cells. The cells were serum-starved for 24h before incubation with PKI166
(0.5 or 5.0mM) for 1h, then stimulation with EGF (50ngml
 1) for 15min
before preparation of protein lysates. Phosphorylation of the growth factor
receptors was detected with antibodies recognising the activated forms of
HER2 and EGFR. The same filters were then reprobed with antibodies
recognising the ‘total’ receptors.
EGFR and ERK1/2 phosphorylation in breast cancer
DC Lev et al
798
British Journal of Cancer (2004) 91(4), 795–802 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
spathways were contributing to the growth and survival of the cells.
The effects of the inhibitors were not related to downregulation of
total ERK1/2 proteins, as the levels did not decrease with treatment
(Figure 5).
DISCUSSION
Due to growing disappointment with current therapies for breast
cancer, which have not lead to significant alleviation of metastatic
disease, more attention has been focused on developing novel
targeted therapies (Bange et al, 2001). Major targets are members
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Figure 3 PKI166 and U0126 induce apoptosis and increase proportions of cells in G1. The percentages of cells in sub-G1/hypodiploid (solid bars) and in
G1 (cross-hatched bars) following 48h treatment with PKI166 (0.5 or 5.0mM) or U0126 (10mM), and the combination were determined by FACS analysis of
propidium iodide stained cells. Values shown are the mean and SD from three independent experiments, and * indicates a significant difference from the
control values, Po0.05, Student’s t-test.
PKI 166 (M) –
– + – + – +
– 0.5 0.5 5.0 5.0
U0126 (10M)
MDA-MB-231
SUM 149
p27
Actin
p27
Actin
Figure 4 Induction of p27
KIP1 by PKI166 and U0126, detected by
immunoblotting lysates of cells from the same experiment described in
Figure 3. Either inhibitor induced expression of the cyclin-dependent kinase
inhibitor in SUM149 cells, while only U0126 produced detectable protein in
MDA-MB-231 cells.
PKI166 ––
–– + – ++
0.5 5.0 0.5 5.0
U0126
MDA-MB-231
MDA-MB-435
SUM 149
MDA-MB-468
pERK1/2
ERK1/2
pERK1/2
ERK1/2
pERK1/2
ERK1/2
pERK1/2
ERK1/2
1.0 0.14 0.04 0.07 0.03 0.01
1.0 0.27 0.26 0.22 0.03 0.03
1.0 0.9 0.9 0.07 0.06 0.04
1.0 1.0 1.0 0.84 0.53 0.29
Figure 5 Immunoblots showing pERK1/2 and total ERK1/2 in lysates of
cells serum-starved for 24h, then treated with PKI166 (0.5 or 5.0mM)o r
UO126 (10mM) as indicated, for 1h before preparation of the lysates.
Values of the relative expression of pERK1/2 expressed as a ratio of total
ERK1/2 expression, and corrected for equal loading relative to actin (not
shown) indicated below the immunoblots were determined by densito-
metry, and expressed as proportion of the control values (cells treated with
DMSO).
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sof the erbB family of growth factor receptors, principally EGFR and
HER2, which are known to play important roles in breast cancer
pathogenesis (Lacroix et al, 1989; Slamon et al, 1990; Klijn et al,
1992). As the targeted agents move into clinical trials it will be
important to have a clear understanding of the EGFR-dependent
pathways and their patterns of expression and activation. The
present study focuses on the relationship between EGFR and the
MAPK pathway. This choice was not arbitrary, as this pathway is
one of the major downstream signalling pathways from EGFR.
Activated ERK1/2 control many processes that are central to
malignant progression, including cell growth, apoptosis and
migration (Pages et al, 1993; Campbell et al, 1995; Hoshino et al,
1999; Schramek, 2002).
Disrupting regulation of the MAPK pathway can predispose cells
to undergo tumorigenic transformation, as illustrated by the
position of the ras oncogene upstream of ERK (Zhang et al, 1993).
Transfection with constitutively active forms of MEK resulted in
transformation, increased sensitivity to, or independence from
growth factors in vitro, and tumorigenicity in vivo (Brunet et al,
1994; Mansour et al, 1994). A few studies have assessed the
expression of activated MAPK in different clinical tumour
specimens, and asked if this has any clinical or biological
correlation. In renal cell carcinoma, MAPK activation correlated
with MAPK kinase activation and Raf-1 activation (Oka et al,
1995), while for hepatocarcinomas a relationship was reported
between ERK1/2 activation and expression of the transcription
factor c-Fos and cyclin D1 (Ito et al, 1998). High levels of activated
MAPK were found in high grade and advanced stage prostate
cancers, suggesting a link between elevated ras signalling and
advanced disease (Gioeli et al, 1999). Activated MAPK was also
reported in glial tumours and in a group of oligodendrogliomas, an
increase in the proportions of cells expressing activated MAPK
corresponded with malignant progression (Mandell et al, 1998).
Sivaraman et al (Itoh et al, 2002) provided the first demonstration
of MAPK activation in human breast cancer tissues, comparing
primary breast cancer with benign lesions using substrate-based
MAPK enzyme assays and immunoblotting. They found signifi-
cantly less MAPK activity to be in benign breast tissues compared
with invasive breast cancers. In another study, a 2.5-fold increase
in activated MAPK was seen in breast cancer specimens compared
to normal breast tissue, and this was associated with poor
prognosis and decreased sensitivity to endocrine therapy, and
with expression of phosphorylated c-jun, a transcription factor
activated by MAPK (Gee et al, 2000; Donovan et al, 2001).
Phosphorylated MAPK is also thought to be involved in
acquisition of resistance to antioestrogen treatment in ER-positive
cells, as it has been shown to be one of the characteristics of
advanced breast cancer and involved in the progression to
oestrogen-independence (Jeng et al, 2000; Gee et al, 2001). In a
recent study of human breast cancer specimens, activated MAPK
detected by immunohistochemistry was increased in lymph node
metastases compared with primary tumours, suggesting a role in
the metastatic process (Adeyinka et al, 2002).
The causes of MAPK activation in human cancers vary among
the different types of cancer. In many, ERK activation reflects the
activity of mutated forms of ras. However, in breast cancer
activating ras mutations are relatively rare, reported in only 5% of
cases (Bos, 1989; Dickson et al, 1991), leading to the view that ras
mutations do not have an important role in this disease. However,
it is not easy to distinguish whether an apparent constitutive
elevation in basal activity of ERK1/2 is due to an inherent
alteration in the pathway regulation, or if the pathway is more
sensitive to stimulation by an exogenous ligand. One possible
explanation can still be connected to ras, as any one of the three
major genes (H-ras, K-ras, N-ras) may be overexpressed in breast
cancer, and this correlates with cancer progression (Von Lintig
et al, 2000). Wild-type ras is subject to regulation by GTPase
activating proteins and guanine nucleotide exchange factors by
different upstream receptors, one of which is EGFR. A correlation
between overexpression of EGFR and enhanced ERK activity has
been previously suggested (Xing and Imagawa, 1998), and the
present study explores the relationship further. The results, using
several different cell lines in an attempt to mimic the heterogeneity
of clinical breast cancer cases, do not fully support the previous
report. We found that the levels of activated ERK1/2 did not
uniformly correlate with EGFR or HER2 status in the different cell
lines, and that different combinations of EGFR and low pERK1/2,
or low EGFR and high pERK1/2 were found in the panel of cell
lines studied. The results suggest that although EGFR and HER2
can signal through ERK1/2, an increase in receptors does not
necessarily result in sustained ERK1/2 activity. Also, the hyper-
activity of ERK1/2 in some of the cells studied may be secondary to
other genetic, or epigenetic, alterations, for example the K-ras
mutation in the MDA-MB-231 cell line (Davidson et al, 1987).
Another potential explanation for elevation in ERK1/2 activation is
a change in the expression or activation of specific threonine/
tyrosine phosphatases that inactivate pERK1/2 (Tonks and Neel,
1996; Cook et al, 1997). Recently, it was shown that the expression
of the MKP-1 phosphatase in Rat-1 cells was controlled by growth
factors acting via ERK- and calcium-dependent pathways. Treat-
ment with the phosphatase inhibitor sodium orthovanadate
elevated basal ERK1/2 activity in the absence of growth factors
(Cook et al, 1997). Thus, an attenuation of phosphatase expression
or activity might be manifest as a rise in basal ERK1/2 activation.
Administration of PKI166 has been shown to be effective in
controlling tumour growth and metastasis when used in combina-
tion with chemotherapy agents in preclinical models, including
pancreatic cancer (Bruns et al, 2000), bladder and renal cell cancer
(Baker et al, 2002). While used to target EGFR phosphorylation,
PKI166 also inhibits phosphorylation of HER2 (Traxler et al,
2001). In this study the high HER2-expressing SKBR3 cell line was
one of the more sensitive to growth inhibition and apoptosis
induced by PKI166. As previously reported (Moasser et al, 2001;
Bishop et al, 2002), and supported by the results of this study, a
relatively high level of the target is needed to see the efficacy of an
anti-EGFR agent. Similar to these previous reports, we also found
that not every cell line expressing high levels of EGFR was growth
inhibited by PKI166. Insensitive lines either had relatively little
receptor expression or had a high basal activity of ERK1/2, the
latter of which appeared to protect the cells from EGFR-signalling
blockade. The prediction from this in the clinical situation is that
while some tumours expressing high levels of EGFR will respond
well to EGFR inhibitors, others may not. Determination of the
levels of pERK1/2, in addition to expression of EGFR, in
pretreatment biopsies may allow prediction of the response of a
patient to anti-EGFR therapy.
Blocking EGFR signalling has been shown to stabilise the cyclin-
dependent kinase inhibitor p27
KIP1 and leads to G1 cell cycle arrest
(Busse et al, 2000; Di Gennaro et al, 2003). PKI166 alone, and in
combination with U0126 reduced ERK1/2 activity, and induced
p27
KIP1 expression in SUM149 cells. In contrast, only treatment
with U0126 was able to induce G1 arrest and p27
KIP1 in MDA-MB-
231 cells, which were relatively insensitive to PKI166 alone. U0126
blocks MAPK signalling pathways by preventing activation of
MEK1/2 (Davies et al, 2000), and it is also reported to block ERK5/
BMK1 phosphorylation at the concentration used in this study
(Kamakura et al, 1999). Signalling through ERK5 contributes to
cyclin D1 regulation in breast cancer cells (Mulloy et al, 2003).
Thus, the antiproliferative effects of U0126 may be due to the
inhibition of ERK1/2 and ERK5 mediated signalling.
This study focused on the consequences of blocking EGFR and
ERK signalling. However, even in the most sensitive cell lines, such
as SUM149 and MDA-MB-468, in which ERK1/2 phosphorylation
was almost completely inhibited, the growth inhibition or
apoptosis induction were not more than 50–80% of control
values. One explanation is that additional signalling pathways,
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viability of the cells. The phosphoinositide 3-kinase (PI3K)
pathway is sensitive to EGFR-signalling blockade, promoting cell
death through inhibition of AKT (Busse et al, 2000; Anderson et al,
2001; Moasser et al, 2001; Clark et al, 2002). PKI166 reduced basal
levels of AKT activity in SUM 149, SKBR3 and MDA-MB-468, and
inhibited EGF-induced AKT activity in MDA-MB-231 cells (data
not shown). Similar to what this study found for ERK1/2 activity,
the activation status of the PI3K/AKT pathway may influence
responses to inhibitors. For example, Moasser et al (2001) found
that MDA-MB-468 cells were relatively resistant to the tyrosine
kinase inhibitor ZD1839, and this was attributed to the high basal
AKT activity, resulting from deletion of the PTEN tumour
suppressor (Lu et al, 1999).
The present study underscores the fact that the overexpression
of EGFR or HER2 does not predict sensitivity to a therapy targeted
to these receptors. Moreover, strategies designed to block more
than one protein or pathway are likely to potentiate antiprolifera-
tive responses. Considering that cells in advanced breast cancers
can have multiple mutations and genetic alterations, it is likely that
therapeutic combinations targeting multiple pathways or key
proteins will be more effective than single or nontarget-specific
agents. Although ERK1/2 are not abnormal proteins, expression at
abnormally high and sustained levels may be a potential target for
pharmacological intervention for proliferative diseases, including
cancer. The blockade of the MAPK pathway with an MEK inhibitor
given orally suppressed the growth of colon tumours transplanted
in mice, with no apparent side effects (Sebolt-Leopold et al, 1999).
In our study, the combination of U0126 with PKI166 resulted in
significant growth inhibition and apoptosis in cells expressing
EGFR and pERK1/2. These results suggest that there is a strong
molecular rationale supporting the continued development of
inhibitors of the MAPK pathway, and for using them in
combination with inhibitors of growth factor receptors such as
the tyrosine kinase inhibitor PKI 166.
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